Claims for Patent: 6,372,471
✉ Email this page to a colleague
Summary for Patent: 6,372,471
| Title: | Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| Abstract: | The present invention is directed to nucleic acids encoding vespid venom enzymes, or fragments thereof, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to expression of such nucleic acids to produce recombinant vespid venom enzymes, or recombinant fragments, derivatives or analogs thereof. Such recombinant products are useful for diagnosis of allergy and for therapeutic treatment of allergy. In specific embodiments, the present invention provides nucleic acids encoding, and complete nucleotide and amino acids sequences for, vespid venom phospholipase, for example, Polistes annularis phospholipase A1, and vespid venom hyaluronidase, for example, Polistes annularis hyaluronidase. Moreover, agents and pharmaceutical compositions are disclosed which modulate the immune system's ability to attack an immunogen, along with methods of using such agents and pharmaceutical compositions to modulate immune response, or to treat immune system related diseases or disorders, or symptoms related thereto. |
| Inventor(s): | Te Piao King |
| Assignee: | Rockefeller University |
| Application Number: | US09/166,205 |
Details for Patent 6,372,471
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 25, 2003 | ⤷ Get Started Free | 2018-10-01 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | April 12, 2006 | ⤷ Get Started Free | 2018-10-01 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 03, 2007 | ⤷ Get Started Free | 2018-10-01 |
| Takeda Pharmaceuticals U.s.a., Inc. | ADVATE | antihemophilic factor (recombinant), plasma/albumin free method | For Injection | 125063 | July 12, 2012 | ⤷ Get Started Free | 2018-10-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch